Ken Griffin Verve Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $21,560 - $38,514	-4,900 Reduced 39.52%	7,500 $36,000
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $120,904 - $324,866	-25,400 Reduced 67.2%	12,400 $60,000
Q1 2024 May 15, 2024	SELL	$10.81 - $17.96 $65,941 - $109,556	-6,100 Reduced 13.9%	37,800 $501,000
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $106,964 - $226,270	12,100 Added 38.05%	43,900 $611,000
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $304,914 - $555,894	26,700 Added 523.53%	31,800 $421,000
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $14,674 - $21,890	-1,100 Reduced 17.74%	5,100 $95,000
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $1.51 Million - $2.54 Million	-105,800 Reduced 94.46%	6,200 $89,000
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $498,015 - $1.14 Million	-27,900 Reduced 19.94%	112,000 $2.17 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $48,453 - $128,619	3,100 Added 2.27%	139,900 $4.81 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $361M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.